Melatonin, an inhibitory agent in breast cancer
- 26 March 2016
- journal article
- review article
- Published by Springer Nature in Breast Cancer
- Vol. 24 (1) , 42-51
Abstract
The heterogeneous nature of breast cancer makes it one of the most challenging cancers to treat. Due to the stimulatory effect of estrogen in mammary cancer progression, anti-estrogenic agents like melatonin have found their way into breast cancer treatment. Further studies confirmed a reverse correlation between nocturnal melatonin levels and the development of mammary cancer. In this study we reviewed the molecular inhibitory effects of melatonin in breast cancer therapy. To open access the articles, Google scholar and science direct were used as a motor search. We used from valid external and internal databases. To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death. To retrieval the related articles, we continuously search the articles from 1984 to 2015. The relevance and the quality of the 480 articles were screened; at least we selected 80 eligible articles about melatonin molecular mechanism in breast cancer. The results showed that melatonin not only inhibits breast cancer cell growth, but also is capable of inhibiting angiogenesis, cancer cell invasion, and telomerase activity. Interestingly this hormone is able to induce apoptosis through the suppression or induction of a wide range of signaling pathways. Moreover, it seems that the concomitant administration of melatonin with other conventional chemotherapy agents had beneficial effects for patients with breast cancer, by alleviating unfavorable effects of those agents and enhancing their efficacy. The broad inhibitory effects of melatonin in breast cancer make it a promising agent and may add it to the list of potential drugs in treatment of this cancer.Keywords
This publication has 70 references indexed in Scilit:
- Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarksAging Clinical and Experimental Research, 2013
- Increasing doxorubicin activity against breast cancer cells using PPARγ‐ligands and by exploiting circadian rhythmsBritish Journal of Pharmacology, 2013
- Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinomaJournal of Pineal Research, 2013
- Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer CellsEvidence-Based Complementary and Alternative Medicine, 2013
- Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survivalBreast Cancer Research and Treatment, 2012
- Survival Rate of Breast Cancer Based on Geographical Variation in Iran, a National StudyIranian Red Crescent Medical Journal, 2012
- Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathwayBreast Cancer Research, 2010
- Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cellsBritish Journal of Cancer, 2009
- The role of melatonin in immuno‐enhancement: potential application in cancerInternational Journal of Experimental Pathology, 2006
- Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activityInternational Journal of Cancer, 2005